vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $51.3333.

Several equities research analysts have recently weighed in on the stock. BTIG Research assumed coverage on shares of vTv Therapeutics in a research report on Wednesday, November 19th. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Cowen assumed coverage on vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th.

Institutional Trading of vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP lifted its holdings in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Down 13.3%

Shares of VTVT opened at $35.58 on Monday. The firm has a market cap of $140.11 million, a price-to-earnings ratio of -10.72 and a beta of 0.48. The business’s 50 day moving average is $32.45 and its two-hundred day moving average is $23.27. vTv Therapeutics has a 52-week low of $13.20 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.